November 10, 2022
Reston, VA—Nearly 70 percent of breast cancer patients could find out if their cancer has spread to their lymph nodes without having to undergo an invasive sentinel node biopsy. New research published ahead of print in The Journal of Nuclear Medicine shows that with the help of machine learning (a type of artificial intelligence), axillary lymph node metastasis can be reliably ruled out based on imaging with PET/MRI.
The presence of lymph node metastases plays a crucial role in treatment planning, especially regarding the extent of surgery and radiation. Therefore, it is of high clinical relevance to distinguish patients with lymph node metastases from patients without lymph node metastases.
“Sixty percent of patients do not have lymph node metastases at initial diagnosis of breast cancer,” said study author Janna Morawitz, MD, radiology resident at the Institute for Diagnostic and Interventional Radiology at the University Hospital Düsseldorf in Germany. “As such, it would be desirable to be able to prove negative lymph node status by imaging with a high degree of certainty to spare these patients the invasive procedure of biopsy or surgery.”
In the study, researchers sought to determine whether machine learning prediction models could determine lymph node status in PET/MRI examinations as accurately as an experienced radiologist could. A total of 303 primary breast cancer patients from three medical centers were recruited for the study and were divided into a training group sample and a testing group sample.
All patients underwent MRI and dedicated whole-body 18F-FDG PET/MRI. The imaging datasets were evaluated for axillary lymph node metastases based on structural and functional features. Machine learning models were developed based on the MRI and PET/MRI training group sample and were then applied to the testing group sample.
The diagnostic accuracy of MRI was 87.5 percent for both radiologists and the machine learning algorithm. For PET/MRI, the accuracy was 89.3 percent for radiologists and 91.2 percent for machine learning. After adjusting the machine learning model for PET/MRI, a sensitivity of 96.2 percent and a specificity of 68.2 percent was achieved.
“Based on the information gleaned from the MRI and PET/MRI scans, decision trees can be made to help radiologists—especially younger radiologists—determine whether a sentinel lymph node biopsy is warranted,” noted Morawitz. “Incorporating this model into daily practice could potentially replace sentinel lymph node biopsy in the future.”
|Graphical Abstract: Patients with newly diagnosed breast cancer receive a PET/MRI scan to investigate axillary lymph node involvement. The radiologist then assesses whether lymph node involvement is present (nodal positive vs. nodal negative) based on easily assessable morphological and metabolic lymph node criteria. Based on these data, a random forest model is trained. Thus, the most important lymph node criteria relevant for the assessment of the lymph node status are determined. By adjusting the threshold, the sensitivity can now be increased by means of a random forest in such a way that 68.2% of patients can be spared an axillary biopsy.|
The authors of “Clinical decision support for axillary lymph node staging in newly diagnosed breast cancer patients based on 18F-FDG PET/MRI and machine-learning” include Janna Morawitz, Christian Rubbert, Nils-Martin Bruckmann, Frederic Dietzel, Gerald Antoch, Julian Caspers, and Julian Kirchner, Department of Diagnostic and Interventional Radiology, Medical Faculty, University Düsseldorf, Düsseldorf, Germany; Benjamin Sigl, Pascal Baltzer, Panagiotis Kapetas, Thomas Helbich, and Paola Clauser, Department of Biomedical Imaging and Image-Guided Therapy, Division of General Radiology, Medical University of Vienna, Austria; Lena J. Häberle, Institute of Pathology, Medical Faculty, Heinrich-Heine-University and University Hospital Düsseldorf, Düsseldorf, Germany; Saskia Ting, Institute of Pathology, University Hospital Essen, West German Cancer Center, University Duisburg-Essen and the German Cancer Consortium (DKTK) Essen, Germany; Svjetlana Mohrmann and Eugen Ruckhäberle; Department of Gynecology, University of Düsseldorf, Medical Faculty, Düsseldorf, Germany; Ann-Kathrin Bittner and Oliver Hoffmann, Department of Gynecology and Obstetrics, University Hospital Essen, University of Duisburg-Essen, Essen, Germany; Wolfgang P. Fendler, Christoph Rischpler, and Ken Herrmann, Department of Nuclear Medicine, University of Duisburg-Essen and German Cancer Consortium (DKTK) University Hospital Essen, Essen, Germany; Benedikt M. Schaarschmidt and Lale Umutlu, Department of Diagnostic and Interventional Radiology and Neuroradiology, University Hospital Essen, University of Duisburg-Essen, Essen, Germany; and Andreas Stang, Institute of Medical Informatics, Biometry and Epidemiology, Essen University Medical Center, Essen, Germany.
Please visit the SNMMI Media Center for more information about molecular imaging and precision imaging. To schedule an interview with the researchers, please contact Rebecca Maxey at (703) 652-6772 or email@example.com.
About JNM and the Society of Nuclear Medicine and Molecular Imaging
The Journal of Nuclear Medicine (JNM) is the world’s leading nuclear medicine, molecular imaging and theranostics journal, accessed 15 million times each year by practitioners around the globe, providing them with the information they need to advance this rapidly expanding field. Current and past issues of The Journal of Nuclear Medicine can be found online at http://jnm.snmjournals.org.
JNM is published by the Society of Nuclear Medicine and Molecular Imaging (SNMMI), an international scientific and medical organization dedicated to advancing nuclear medicine and molecular imaging—precision medicine that allows diagnosis and treatment to be tailored to individual patients in order to achieve the best possible outcomes. For more information, visit www.snmmi.org.